drugset
drugset / Trial / NCT01215786

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01215786 ↗

Phase 1 Completed 50 enrolled Allergan
RandomizedParallel-groupTriple-blindTreatment

Summary

This is an exploratory study that will evaluate the safety and pharmacodynamics of up to 3 doses of AGN-207281 based on an ongoing review of data during the study period compared with timolol ophthalmic solution or placebo in patients with ocular hypertension or primary open-angle glaucoma.

Timeline

Start
2010-10
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AGN-207281 Unknown 0.3 % Other
Comparator Timolol Other / unclassified 0.5 % Other

Indications

ocular hypertension open-angle glaucoma